Healthcare Jan 11, 2021 10:09 AM (GMT+8) · EqualOcean
Yiou Health reported on January 11 that Suzhou Xinqing Medical Technology Co., Ltd. (hereinafter referred to as "Xinqing medical") has completed round B financing of more than 100 million yuan, which is led by Aurora Borealis venture capital, followed by sugaoxin venture capital, and supported by old shareholders Guoqian venture capital, Anji yunshuo and Taiyu. This round of financing will be mainly used for R & D, clinical trials and production expansion of existing product lines. Xinqing medical was established in Suzhou high tech Zone in May 2017. It mainly researches and develops extracorporeal life support equipment for patients with acute cardiogenic shock, intraoperative circulation protection, acute and severe organ failure and other clinical scenarios. At present, the company's main product lines include minimally invasive invasive invasive artificial heart, extracorporeal magnetic levitation artificial heart, new generation extracorporeal membrane oxygenation system (ECMO), etc. Xinqing medical completed Angel round and a round financing in 2018 and 2019 respectively. Angel round is led by Guoqian venture capital and followed by Taiyu investment. Round a is led by power capital, followed by Huatai health fund and Guoqian venture capital.